Drug Exposure Modeling for Infection-Control Antimicrobials: A Comprehensive Review

Abstract

Drug exposure modeling has become a critical component in optimizing the use of infection-control antimicrobials, enabling tailored therapy that maximizes efficacy and minimizes toxicity and resistance. This review synthesizes current evidence on pharmacokinetic-pharmacodynamic (PK-PD) modeling, highlights epidemiological trends, provides mechanistic insights, and examines recent advances and recommendations in antimicrobial stewardship. The aim is to provide clinicians, researchers, and policy-makers with a robust, evidence-based understanding of how exposure modeling informs the rational use of antimicrobials in infection control.

Introduction

The advent of multidrug-resistant organisms and the complexity of infectious diseases have intensified the need for precision in antimicrobial therapy. Drug exposure modeling, leveraging PK-PD principles, offers a scientific framework for optimizing antimicrobial dosing regimens by predicting drug concentrations at infection sites relative to pathogen susceptibility. Integrating patient-specific variables, pathogen characteristics, and drug properties, this approach facilitates individualized treatment strategies, aligning with contemporary antimicrobial stewardship objectives. This article reviews the state-of-the-art in exposure modeling for infection-control antimicrobials, emphasizing its clinical relevance and translational potential.

Epidemiology / Disease Burden

Infectious diseases remain a major global health challenge, with antimicrobial resistance (AMR) contributing significantly to morbidity, mortality, and healthcare costs. According to the World Health Organization, drug-resistant infections cause an estimated 700,000 deaths annually, projected to rise to 10 million by 2050 if current trends persist. Hospital-acquired infections (HAIs), including bloodstream, respiratory, and urinary tract infections, are frequently managed with broad-spectrum antimicrobials, further fueling resistance. Epidemiological studies underscore the urgent need for optimized antimicrobial utilization, particularly in critical care and immunocompromised populations where infection-control measures are paramount.

Pathophysiology

The pathophysiology of infectious diseases involves complex host-pathogen interactions, with treatment efficacy hinging on the ability of antimicrobials to reach and maintain therapeutic concentrations at the site of infection. Drug exposure modeling elucidates how absorption, distribution, metabolism, and excretion (ADME) processes influence systemic and tissue drug levels. Variability in these processes due to age, organ dysfunction, or comorbidities can lead to subtherapeutic exposure or toxicity. Pathogen characteristics, such as biofilm formation and intracellular localization, further complicate treatment, necessitating models that account for altered pharmacodynamics at infection sites.

Risk Factors

Several patient- and pathogen-related risk factors modulate antimicrobial exposure and infection outcomes. These include renal and hepatic impairment, extremes of age, obesity, genetic polymorphisms affecting drug metabolism, and alterations in protein binding. Pathogen factors such as resistance mechanisms, inoculum size, and virulence also impact required drug exposure for eradication. Hospital settings, invasive procedures, and immunosuppression increase susceptibility to multidrug-resistant infections, underscoring the need for exposure models that integrate clinical risk stratification with microbiological data.

Clinical Features

The clinical presentation of infections requiring targeted infection-control antimicrobials is heterogeneous, ranging from localized symptoms (e.g., cellulitis, pneumonia) to systemic manifestations (sepsis, septic shock). Early recognition and timely initiation of appropriate therapy are crucial for patient outcomes. However, interpatient variability in drug exposure can result in treatment failures or adverse effects, particularly in vulnerable cohorts. Drug exposure modeling supports clinicians in identifying patients at risk for under- or overexposure, thus guiding dose adjustments in real time.

Diagnosis

Accurate diagnosis of infectious diseases relies on a combination of clinical assessment, laboratory biomarkers, and microbiological confirmation. Diagnostic stewardship, integrated with drug exposure modeling, enhances the precision of antimicrobial therapy by linking pathogen identification and susceptibility with individualized dosing strategies. Therapeutic drug monitoring (TDM) is a cornerstone in this approach, especially for agents with narrow therapeutic indices, such as vancomycin and aminoglycosides. Model-informed precision dosing (MIPD) platforms utilize real-time patient data to inform dosing, improving diagnostic and therapeutic alignment.

Treatment & Management

Effective management of infections mandates the selection of appropriate antimicrobials, optimal dosing, and duration of therapy. Traditional dosing regimens, often based on population averages, may not account for individual pharmacokinetic variability, leading to inadequate drug exposure. Drug exposure modeling incorporates patient-specific data such as renal function, body weight, and severity of illness to refine dosing. By linking drug concentrations to clinical outcomes (e.g., microbiological eradication, resolution of symptoms), this approach supports rational therapy and stewardship interventions aimed at reducing resistance and toxicity.

Recent Advances / Emerging Therapies

Recent advances in exposure modeling include Bayesian forecasting, machine learning algorithms, and integration with electronic health records (EHRs) to facilitate real-time dose optimization. Novel antimicrobials and adjunctive agents are being evaluated using advanced PK-PD models to determine optimal regimens for resistant pathogens. Population pharmacokinetic analyses, coupled with Monte Carlo simulations, enable the prediction of probability of target attainment (PTA) across diverse patient groups. The emergence of model-informed precision dosing platforms is transforming clinical practice by providing actionable recommendations at the point of care, with demonstrated benefits in reducing adverse events and improving therapeutic outcomes

Guideline Recommendations

International guidelines from organizations such as the Infectious Diseases Society of America (IDSA), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and World Health Organization increasingly emphasize the role of PK-PD modeling and TDM in antimicrobial stewardship. Recommendations include individualized dosing for agents with high interpatient variability, routine use of exposure models in critical care, and implementation of MIPD for high-risk populations. Collaborative efforts between clinicians, pharmacists, and microbiologists are essential for translating exposure modeling into routine practice and optimizing infection-control strategies.

Conclusion

Drug exposure modeling represents a paradigm shift in the management of infectious diseases, enabling precision antimicrobial therapy that balances efficacy, safety, and stewardship. By integrating clinical, pharmacological, and microbiological data, exposure models inform individualized treatment, reduce the risk of resistance, and support guideline-driven care. Ongoing research and technological innovation will further refine these approaches, with the ultimate goal of improving patient outcomes and preserving the effectiveness of infection-control antimicrobials for future generations.